A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants

Exclusion Criteria

• •Participants having body weight of ≥50 kilogram (kg) and \<100 kg
• •Participants having a clinical laboratory profile within the normal range or must have results that do not show clinically significant abnormalities, as judged by the investigator at screening.
• •Contraceptive use by men or women participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
• •Participants who are female at birth are eligible to participate if at least one of the following conditions applies:
• •Not pregnant or breastfeeding and at least one of the following conditions applies:
• •Is not a participant of childbearing potential (POCBP) or Is a POCBP and agree to use an acceptable contraceptive method as described in Section 10.4 from 3 weeks prior to the start of this study and during the study. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.
• •A POCBP must have a negative highly sensitive serum pregnancy test on Day -1, prior to the first dose of study intervention All participants in the study should be counseled on safer sexual practices including the use and benefit/risk of effective barrier methods (e.g., male condom).
• •The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a POCBP with an early undetected pregnancy.
• •Capable of giving written informed consent.
• •Hypertension that is not well controlled.
• +22 more criteria